COMPLETED

Acute Plasma Abeta Responses to Stress

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Research has shown that activation of the sympathetic nervous system for extended periods or during certain times in life can increase the risk for Alzheimer's disease. Some research in animal models show that acute activation of the sympathetic nervous system through stress exposure can increase certain Alzheimer's disease-related biomarkers, such as amyloid-beta, within hours of exposure. However, how acute sympathetic nervous system activation via stress exposure affects amyloid-beta levels in humans has yet to be examined. In this study, the investigators will examine whether brief increases in sympathetic activation result in immediate changes in plasma amyloid-beta levels in the five hours after exposure.

Official Title

Effects of Acute Stress Exposure on Plasma Beta-amyloid Levels

Quick Facts

Study Start:2023-12-05
Study Completion:2024-12-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT05521919

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Healthy adult weighing at least 110 pounds
  2. * No chronic conditions or illness
  3. * Taking no medications or drugs that might alter the stress response (e.g., corticosteroids, beta-blockers, and others)
  4. * Not using any hormone-containing medication (e.g., hormonal contraceptives, hormone replacement, etc.)
  5. * No contraindications for cold pressor test exposure (high blood pressure, heart disease, dysrhythmia, peripheral vascular disease, any other cardiovascular disorder, diabetes, vasculitis, lupus, tingling or numbness in the hands and/or feet, cryoglobulinemia, and Reynaud's phenomenon)
  6. * No history of fainting during blood draws
  7. * No phobia of having their blood drawn
  8. * No general history of fainting or seizures
  9. * Not currently diagnosed with a mood disorder (e.g., major depressive disorder)
  10. * Not pregnant in the past 12 months
  11. * Not lactating in the past 12 months
  12. * Not trying to become pregnant if premenopausal
  13. * Experienced natural menopause if postmenopausal
  14. * Be non-smokers
  15. * Be fluent in English
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Locations (Sites)

University of Southern California
Los Angeles, California, 90089
United States

Collaborators and Investigators

Sponsor: University of Southern California

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-05
Study Completion Date2024-12-10

Study Record Updates

Study Start Date2023-12-05
Study Completion Date2024-12-10

Terms related to this study

Keywords Provided by Researchers

  • Stress Reaction
  • Stress
  • Amyloid-Beta

Additional Relevant MeSH Terms

  • Stress Reaction
  • Stress Physiology